VERU Stock Summary and Trading Ideas (Veru | NASDAQ:VERU)

Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology and acute respiratory distress syndrome (ARDS). The company is also in the late stage development of certain drugs for management of breast and prostate cancers. It also has a sexual health program which includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in single segment and generates revenue from USA which is the key revenue generating market, South Africa and other regions.

Veru trades on the NASDAQ stock market under the symbol VERU.

As of May 6, 2024, VERU stock price declined to $1.61 with 653,595 million shares trading.

VERU has a beta of 0.37, meaning it tends to be less sensitive to market movements. VERU has a correlation of 0.00 to the broad based SPY ETF.

VERU has a market cap of $235.53 million. This is considered a Small Cap stock.

In the last 3 years, VERU stock traded as high as $24.55 and as low as $.36.

The top ETF exchange traded funds that VERU belongs to (by Net Assets): VTI, VXF, IWC, AVSC.

VERU stock has underperformed the market in the last year with a return of +26.8%, while SPY returned +27.7%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in VERU shares. However, VERU has outperformed the market in the last 3 month and 2 week periods, returning +222.0% and +22.9%, while SPY returned +4.4% and +3.9%, respectively. This indicates VERU has been having a stronger performance recently.

VERU support price is $1.47 and resistance is $1.80 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VERU stock will trade within this expected range on the day.